Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Shire plc | dp73566_ex9902.htm |
| EX-99.1 - EXHIBIT 99.1 - Shire plc | dp73566_ex9901.htm |
| 8-K - FORM 8-K - Shire plc | dp73566_8k.htm |
Exhibit 99.3
| Press
Release www.shire.com |
 |
Director/PDMR Shareholding
March 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by persons discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | ||
| a) | Name | Perry Sternberg | |
| 2. | Reason for the notification | ||
| a) | Position / status | Head of US Commercial - PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Vesting of Restricted Stock Units (“RSUs”) in respect of notional ADSs awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016. In accordance with the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 5. below.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A | 217 | ||
| d) |
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | N/A | |
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction |
Automated disposal of ADSs in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
| |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $182.59 | 72 | ||
| d) |
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | NASDAQ | |
| 6. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Vesting of Restricted Stock Units (“RSUs”) in respect of notional ADSs awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 27, 2015. In accordance with the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 7. below.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A | 141 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of transaction | N/A | |
| 7. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc American Depositary Shares (“ADSs”)
| |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Automated disposal of ADSs in relation to the vesting of RSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $182.59 | 56 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | NASDAQ | |
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”) | |
| a) | Name | Kim Stratton |
| 2. | Reason for the notification | |
| a) | Position / status | Head of International Commercial - PDMR |
| b) | Initial notification / amendment | Initial notification |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Shire plc |
| b) | LEI | 54930005LQRLI2UXRQ59 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument |
Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
|
| Identification code | ISIN: JE00B2QKY057 | |
| b) | Nature of the transaction | Vesting of Restricted Stock Units (“RSUs”) in respect of notional Ordinary Shares awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016. In accordance with the rules of the LTIP, upon vesting the number of Ordinary Shares to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting. (Details of related disposal of Ordinary Shares are referenced in section 5. below.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A | 368 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | N/A | |
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
| |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Automated disposal of Ordinary Shares in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £48.31 | 111 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | London Stock Exchange | |
| 6. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Vesting of Restricted Stock Units (“RSUs”) in respect of notional Ordinary Shares awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 27, 2015. In accordance with the rules of the LTIP, upon vesting the number of Ordinary Shares to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting. (Details of related disposal of ADSs are referenced in section 7. below.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A | 302 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | N/A | |
| 7. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument |
Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
| |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Automated disposal of Ordinary Shares in relation to the vesting of RSUs referenced in section 6. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £48.31 | 91 | ||
| d) |
Aggregated information
- Aggregated volume
- Price |
N/A (single transaction) | |
| e) | Date of the transaction | February 27, 2017 | |
| f) | Place of the transaction | London Stock Exchange | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | ikarp@shire.com | +1 781 482 9018 |
| Robert Coates | rcoates@shire.com | +44 1256 894874 |
| Media | ||
| Lisa Adler | lisa.adler@shire.com | +1 617 588 8607 |
| Debbi Ford | debbi.ford@shire.com | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com